Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using a proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform. The Company’s SMNH compounds are small segments of nucleic acids that are designed to selectively target and modulate the activity of specific proteins implicated in various disease states.
Spring Bank is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases. It has designed SB 9200 to selectively activate within infected cells the cellular proteins retinoic acid-inducible gene 1, or RIG-I, and nucleotide-binding oligomerization domain-containing protein 2, or NOD2, to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense.
Net income (FY, 2016)
EBIT (FY, 2016)
Market capitalization (28-Jun-2017)
Closing share price (28-Jun-2017)
General and administrative expense
Operating expense total
Additional Paid-in Capital
Depreciation and Amortization
Cash From Operating Activities
Purchases of PP&E
Cash From Investing Activities
Cash From Financing Activities